摘要: In recent years, the role of pathology in breast cancer has changed dramatically. Currently, it no longer a purely diagnostic role, based exclusively on morphology. Pathologists are now asked to provide some information about prognostic and predictive factors, other words risk assessment choice best treatment, according Veronesi’s paradigm: “from maximum tolerable treatment minimum effective treatment”. These changes can be summarized this way: past we were dealing with “what treat”, “how aiming at “whom treat”.